| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Bioceres Crop Solutions Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.10 |
| 52 Week High | US$15.50 |
| 52 Week Low | US$6.66 |
| Beta | 0.44 |
| 11 Month Change | -11.25% |
| 3 Month Change | -30.73% |
| 1 Year Change | -35.45% |
| 33 Year Change | -48.46% |
| 5 Year Change | n/a |
| Change since IPO | -52.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOXD | AR Chemicals | AR Market | |
|---|---|---|---|
| 7D | 2.9% | 2.4% | 8.6% |
| 1Y | -35.5% | -15.0% | 200.6% |
Return vs Industry: BIOXD underperformed the AR Chemicals industry which returned -15% over the past year.
Return vs Market: BIOXD underperformed the AR Market which returned 200.6% over the past year.
Price Volatility
| BIOXD volatility | |
|---|---|
| BIOXD Average Weekly Movement | 7.4% |
| Chemicals Industry Average Movement | 3.6% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in AR Market | 7.0% |
| 10% least volatile stocks in AR Market | 3.9% |
Stable Share Price: BIOXD's share price has been volatile over the past 3 months compared to the AR market.
Volatility Over Time: BIOXD's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of AR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Federico Trucco | investors.biocerescrops.com/home/default.aspx |
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.
Bioceres Crop Solutions Corp. Fundamentals Summary
| BIOXD fundamental statistics | |
|---|---|
| Market cap | US$404.12m |
| Earnings (TTM) | US$3.24m |
| Revenue (TTM) | US$464.83m |
124.6x
P/E Ratio0.9x
P/S RatioIs BIOXD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOXD income statement (TTM) | |
|---|---|
| Revenue | US$464.83m |
| Cost of Revenue | US$283.24m |
| Gross Profit | US$181.59m |
| Other Expenses | US$178.35m |
| Earnings | US$3.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
| Earnings per share (EPS) | 0.052 |
| Gross Margin | 39.07% |
| Net Profit Margin | 0.70% |
| Debt/Equity Ratio | 74.3% |
How did BIOXD perform over the long term?
See historical performance and comparison